GeoMx® Immune Pathways Panel
Helping Your Research
Targeted Content for Cancer Biology
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status.
Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler (DSP).
How it Works
The Immune Pathways panel contains 84 targets plus controls designed for broad coverage of the tumor and tumor microenvironment. GeoMx RNA assays contain in situ hybridization (ISH) probes conjugated to unique DNA indexing-oligonucleotides via a UV-photocleavable linker. After region of interest (ROI) selection on GeoMx DSP and UV cleavage of the oligonucleotides, each DNA oligonucleotide is recognized by a unique Reporter probe that contains a fluorescent barcode. Reporter probes are imaged and counted by the nCounter® Analysis System to provide a direct, digital readout of spatially resolved RNA expression.
- Curated content designed for immuno-oncology research
- Includes tumor and tumor microenvironment coverage plus the Tumor Inflammation Signature (TIS)
- Pre-validated in multiplex format for use in human FFPE or fresh frozen tissue
- Compatible with RNAscope® and antibody morphology markers for tissue imaging
- Customizable with up to 10 additional targets of interest
- For use with nCounter readout and compatible with DSP Data Center
Curated Content for Immuno-Oncology
The GeoMx Immune Pathways panel is designed to profile key aspects of the tumor and tumor microenvironment biology.
- Profile the global immune response
- Assess microenvironment immune activity
- Quantify tumor reactivity
- Measure the 18-gene Tumor Inflammation Signature known to be associated with response to PD-1/PD-L1 inhibitor pathway blockade
Accompanying Morphology Marker Kits are available for tissue visualization and ROI selection.
Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment.
The tumor microenvironment (TME) harbors heterogeneous contents and plays critical roles in tumorigenesis, metastasis, and drug resistance. Therefore, the deconvolution of the TME becomes increasingly essential to every aspect of cancer research and treatment.
Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.
Tumors evade immune surveillance by expressing Programmed Death-Ligand 1 (PD-L1), subsequently inhibiting CD8+ cytotoxic T lymphocyte function. Response of gastric cancer to immunotherapy is relatively low.
Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality.
Immunotherapy has reshaped the field of cancer therapeutics but the population that benefits are small in many tumor types, warranting a companion diagnostic test. While immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) or mismatch repair (MMR) and polymerase chain reaction (PCR) for microsatellite instability (MSI) are the only approved companion diagnostics others are under consideration.